Cancure LLC

Shoreline, WA Doing business as Canzx Biotherapeutics

UEI
XMSVDPZ8ELY1
CAGE
7F7Q6
Primary NAICS
541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
  • Woman Owned Small Business
  • Woman Owned Business
  • Limited Liability Company
Entity structure
Sole Proprietorship
NAICS codes registered in SAM.gov
SAM.gov registration date
Physical address
1531 NE 172nd St, Shoreline, WA 98155, USA

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Recent federal awards

Cancure LLC's 3 most recent federal contract and grant awards, newest first. Amounts are dollars obligated.
Award Agency Obligated Awarded
Feasibility study of a novel NK and CD8 t cells stimulating agent - abstract cell-based therapies, whether NK or t… Grant · R43CA298783 National Cancer Institute $399,444
Development of a novel class of immunotherapeutic antibody for metastatic prostate cancer Grant · R44CA247503 National Cancer Institute $1,499,979
Optimization of a novel cancer immunotherapeutic antibody for human use Grant · R41CA206688 National Cancer Institute $349,994

Quick answers

What is Cancure LLC's UEI?

Cancure LLC's Unique Entity ID (UEI) in SAM.gov is XMSVDPZ8ELY1.

What is Cancure LLC's CAGE code?

Cancure LLC's CAGE code is 7F7Q6.

What is Cancure LLC's primary NAICS code?

Cancure LLC's primary NAICS code is 541715 (Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)).

Where is Cancure LLC located?

Cancure LLC's physical address in SAM.gov is 1531 NE 172nd St, Shoreline, WA 98155, USA.

Is Cancure LLC registered in SAM.gov?

Yes. Cancure LLC's SAM.gov registration is active through December 21, 2026.

What is Cancure LLC's most recent federal award?

Cancure LLC's most recent federal grant award is Feasibility study of a novel NK and CD8 t cells stimulating agent - abstract cell-based therapies, whether NK or t… (R43CA298783), from National Cancer Institute, on August 1, 2025.

On GovTribe

See Cancure LLC's full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login